Frank S. David, MD, PhD

Founder and Managing Director


Frank is a seasoned physician-scientist and corporate strategist at the intersection of business, clinical medicine and basic research. He focuses on helping established and emerging biomedical companies, entrepreneurs, and investors unlock the financial and strategic value of innovative R&D.

After studying molecular biophysics and biochemistry at Yale, Frank received his MD and PhD degrees from Columbia University’s College of Physicians and Surgeons. A board-certified pathologist, he completed his clinical training at Brigham and Women’s Hospital, and then joined the faculty of Harvard Medical School and Brigham and Women’s, where he led an NIH-funded basic research group focused on cell signaling in cancer and kidney development.

As Director in the consulting arm of Leerink Partners (formerly Leerink Swann), a leading healthcare investment bank, Frank led advisory engagements for corporate, commercial, R&D, business development, and investor clients across all major therapeutic areas and business sectors, including biopharma, devices, diagnostics, life sciences tools, and healthcare services. He co-founded Leerink’s Transactional Consulting practice, which advised financial and strategic investors and early-stage companies side-by-side with Leerink's investment banking team. Frank’s strategic support of the Medical Publishing Insights and Practices (MPIP) initiative, a multi-pharma consortium to promote best practices in medical publishing, garnered Leerink the Communiqué Trust and Reputation Award in pharma communications.

Prior to founding Pharmagellan, Frank was Director of Strategy in AstraZeneca’s Oncology Innovative Medicines unit, where he led business strategy efforts from target identification through Phase 2a. He spearheaded initiatives in end-to-end franchise strategy and portfolio valuation, led external communications focused on R&D collaborators and investors, and provided commercial support to pipeline projects and in-licensing teams.

Frank's work in healthcare strategy has appeared in Nature Reviews Drug Discovery, Surgery, Health Affairs Blog, In Vivo, and Pharmaceutical Executive, and he is also the lead author of The Pharmagellan Guide to Biotech Forecasting and Valuation (2017). He has been a speaker and panelist at the International Society of Medical Publication Professionals, the Council of Science Editors, Brigham and Women’s Hospital’s Innovation Grand Rounds, and Mass Bio. Frank also serves as Innovation Strategist at the Brigham Research Institute of Brigham and Women’s Hospital. He blogs about biomedical innovation at Forbes, and maintains an active presence on Twitter (@Frank_S_David).

Frank can be reached directly at





Bryan joined Pharmagellan from AstraZeneca, where he led all US activities for the R&D Information unit. Over his 22-year career in pharma R&D, he has nurtured his passion for using data and analytics to accelerate the discovery and development of new therapies through a variety of positions in research and IT/informatics that have spanned the entire R&D value chain, from target identification to regulatory approval. Bryan received a PhD in chemistry from McGill University, and completed postdoctoral training in chemistry at the California Institute of Technology.

Bryan can be reached directly at



Yevgeniy Feyman


Yevgeniy is an adjunct fellow and former deputy director of health policy at the Manhattan Institute. His prior analyses and research projects have focused on various aspects of health care policy, including the physician shortage, the cost of health care reform, and consumer-directed health care. He is currently a research assistant in the department of health policy at the Harvard T.H. Chan School of Public Health. He received a BA in economics and political science from Hunter College. 




Andy joined Pharmagellan in 2014 as an Associate Consultant.  He recently received his MD at Thomas Jefferson University, and is continuing his clinical training in internal medicine at Harvard's Beth Israel Deaconess Medical Center. Prior to medical school, he was an Associate in Leerink Swann's healthcare strategy consulting practice, where he focused on life cycle management, asset scans, and valuation.  Andy received his BA in biology from the School of Arts and Sciences and his BS in Economics from the Wharton School at the University of Pennsylvania.


frank provenzano, phd


Frank joined Pharmagellan in 2016 as an Associate Consultant. He received his PhD from Columbia University in Biomedical Engineering with a focus on neuroimaging, programming, and neuropsychological analysis. He has applied these techniques to both neurological and psychiatric disorders, and authored several dozen papers and patents. His main focus is on developing new analytical techniques to analyze and visualize healthcare data.




Zachary joined Pharmagellan in 2016 as an Associate Consultant. He received a Masters in Biotechnology & Entrepreneurship from Columbia University, and a BA in Biology & Biological Anthropology from Drew University. Prior to joining Pharmagellan, Zachary was a Senior Associate Researcher at Mount Sinai. His primary research entailed the development of a secreted PTEN phosphatase (PTEN-Long) into a cancer therapeutic with the National Cancer Institute.



We are proud to count the following folks as alumni of the Pharmagellan team: